Inspire Medical Systems, Inc. Announces First Quarter 2023 Financial Results and Updates 2023 Outlook
- Inspire Medical Systems achieved an 84% increase in revenue for the first quarter of 2023, reaching $127.9 million.
- The company's gross margin for the quarter was 84.4%.
- Inspire activated 68 new centers in the U.S. during the first quarter, bringing the total to 973.
- They also created 17 new U.S. sales territories, bringing the total to 242.
- Inspire received FDA approval for pediatric patients with Down syndrome, expanding their market.
- The company finalized countrywide reimbursement in Belgium, improving access to care for patients.
- Inspire raised its full year 2023 revenue guidance to between $580 million to $590 million, an increase from the previous guidance of $560 million to $570 million.
- None.
Inspire Reports Year-over-Year Revenue Growth of
MINNEAPOLIS, May 02, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today reported financial results for the quarter ended March 31, 2023.
Recent Business Highlights
- Generated revenue of
$127.9 million in the first quarter of 2023, an84% increase over the same quarter last year - Achieved gross margin of
84.4% in the first quarter of 2023 - Activated 68 new centers in the U.S. in the first quarter of 2023, bringing the total to 973 U.S. medical centers providing Inspire therapy
- Created 17 new U.S. sales territories in the first quarter of 2023, bringing the total to 242 U.S. sales territories
- Finalized countrywide reimbursement in Belgium
- Received FDA approval for pediatric patients with Down syndrome
"We are excited about our strong performance during the first quarter as the team remained focused on high-quality patient outcomes and delivered exceptional results. Our growth was driven primarily by the increased utilization at existing sites and complemented by the addition of 68 new implanting centers and 17 additional U.S. sales territories," said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. "Based on the strong momentum we are seeing in our business, we are raising our full year 2023 revenue guidance to between
"We also achieved two important milestones in the first quarter," continued Mr. Herbert. "The first was the FDA approval for the pediatric Down syndrome population for patients who are at least 13 years of age. The research has been ongoing for several years and many third-party payers, including Medicare, provide coverage for this population, improving a family’s access to care. The second was countrywide reimbursement approval in Belgium at rates consistent with other countries around the world and the team is already expanding patients’ access to care by opening additional centers and training healthcare providers.”
First Quarter 2023 Financial Results
Revenue was
Gross margin was
Operating expense increased to
Net loss was
As of March 31, 2023, cash, cash equivalents, and investments increased to
Full Year 2023 Guidance
Given the positive trends during the first quarter, Inspire is increasing its full year 2023 revenue guidance to between
The Company is maintaining its full year 2023 gross margin guidance of
Inspire is also maintaining its guidance relating to the opening of new U.S. medical centers of 52 to 56 per quarter, as well as its guidance of 12 to 14 new U.S. territories per quarter for the remainder of 2023.
Webcast and Conference Call
Inspire’s management will host a conference call after market close today, Tuesday, May 2, 2023, at 5:00 p.m. Eastern Time to discuss these results and answer questions.
To access the conference call, please preregister on https://register.vevent.com/register/BI8fb99d2d2d3a438799f239e2a5cac09c. Registrants will receive confirmation with dial-in details.
A live webcast of the event can be accessed on https://edge.media-server.com/mmc/p/pdvidadw. A replay of the webcast will be available on https://investors.inspiresleep.com starting approximately two hours after the event and archived on the site for two weeks.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding full year 2023 financial outlook, our expectations to activate new U.S. medical centers and add new territories per quarter in 2023 and the impact of such additions, and our strategy and investments to grow and scale our business. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.
These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, estimates regarding the annual total addressable market for our Inspire therapy in the U.S. and our market opportunity outside the U.S.; future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing; commercial success and market acceptance of our Inspire therapy; the impact of the ongoing and global COVID-19 pandemic; general and international economic, political, and other risks, including currency, inflation, stock market fluctuations and the uncertain economic environment; our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system or any future products we may seek to commercialize; competitive companies and technologies in our industry; our ability to enhance our Inspire system, expand our indications and develop and commercialize additional products; our business model and strategic plans for our products, technologies and business, including our implementation thereof; our ability to accurately forecast customer demand for our Inspire system and manage our inventory; our dependence on third-party suppliers, contract manufacturers and shipping carriers; consolidation in the healthcare industry; our ability to expand, manage and maintain our direct sales and marketing organization, and to market and sell our Inspire system in markets outside of the U.S.; risks associated with international operations; our ability to manage our growth; our ability to increase the number of active medical centers implanting Inspire therapy; our ability to hire and retain our senior management and other highly qualified personnel; risk of product liability claims; risks related to information technology and cybersecurity; risk of damage to or interruptions at our facilities; our ability to commercialize or obtain regulatory approvals for our Inspire therapy and system, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the U.S. and international markets; and the timing or likelihood of regulatory filings and approvals. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release can be found under the captions “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations“ in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as updated in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 to be filed with the SEC, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor & Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443
Inspire Medical Systems, Inc.
Consolidated Statements of Operations and Comprehensive Loss (unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Revenue | $ | 127,897 | $ | 69,382 | ||||
| Cost of goods sold | 19,888 | 10,004 | ||||||
| Gross profit | 108,009 | 59,378 | ||||||
| Operating expenses: | ||||||||
| Research and development | 25,519 | 11,870 | ||||||
| Selling, general and administrative | 101,988 | 63,564 | ||||||
| Total operating expenses | 127,507 | 75,434 | ||||||
| Operating loss | (19,498 | ) | (16,056 | ) | ||||
| Other expense (income): | ||||||||
| Interest and dividend income | (4,273 | ) | (34 | ) | ||||
| Interest expense | — | 527 | ||||||
| Other (income) expense, net | (17 | ) | 45 | |||||
| Total other (income) expense | (4,290 | ) | 538 | |||||
| Loss before income taxes | (15,208 | ) | (16,594 | ) | ||||
| Income taxes | 216 | 100 | ||||||
| Net loss | (15,424 | ) | (16,694 | ) | ||||
| Other comprehensive loss: | ||||||||
| Foreign currency translation gain | 105 | — | ||||||
| Unrealized gain (loss) on investments | 13 | (143 | ) | |||||
| Total comprehensive loss | $ | (15,306 | ) | $ | (16,837 | ) | ||
| Net loss per share, basic and diluted | $ | (0.53 | ) | $ | (0.61 | ) | ||
| Weighted average common shares used to compute net loss per share, basic and diluted | 29,089,950 | 27,517,268 | ||||||
Inspire Medical Systems, Inc.
Consolidated Balance Sheets (unaudited)
(in thousands, except share and per share amounts)
| March 31, 2023 | December 31, 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 442,132 | $ | 441,592 | ||||
| Investments, short-term | 9,927 | 9,821 | ||||||
| Accounts receivable, net of allowance for credit losses of | 59,766 | 61,228 | ||||||
| Inventories, net | 15,663 | 11,886 | ||||||
| Prepaid expenses and other current assets | 6,090 | 5,505 | ||||||
| Total current assets | 533,578 | 530,032 | ||||||
| Property and equipment, net | 20,920 | 17,249 | ||||||
| Operating lease right-of-use assets | 6,614 | 6,880 | ||||||
| Other non-current assets | 10,735 | 10,715 | ||||||
| Total assets | $ | 571,847 | $ | 564,876 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 36,478 | $ | 26,847 | ||||
| Accrued expenses | 23,390 | 34,339 | ||||||
| Total current liabilities | 59,868 | 61,186 | ||||||
| Operating lease liabilities, non-current portion | 7,185 | 7,536 | ||||||
| Other non-current liabilities | 146 | 146 | ||||||
| Total liabilities | 67,199 | 68,868 | ||||||
| Stockholders' equity: | ||||||||
| Preferred Stock, | — | — | ||||||
| Common Stock, | 29 | 29 | ||||||
| Additional paid-in capital | 844,281 | 820,335 | ||||||
| Accumulated other comprehensive income (loss) | 32 | (86 | ) | |||||
| Accumulated deficit | (339,694 | ) | (324,270 | ) | ||||
| Total stockholders' equity | 504,648 | 496,008 | ||||||
| Total liabilities and stockholders' equity | $ | 571,847 | $ | 564,876 | ||||
FAQ
What is the stock ticker for Inspire Medical Systems?
What was the revenue growth for Inspire in the first quarter of 2023?
How many new centers did Inspire activate in the U.S. during the first quarter?
What was the gross margin for Inspire in the first quarter of 2023?
What was the full year 2023 revenue guidance provided by Inspire?
What recent approvals did Inspire receive?
